Metformin appears to help boost the benefits of immunotherapy drugs used to fight lung tumors, according to a team led by Dr. Sai Yendamuri. He directs thoracic surgery at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y. There was one big catch to the new finding, however.

A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss pharmaceuticals maker said on Tuesday.

A cancer treatment from Roche failed to improve survival in a major lung cancer study, a result that will stoke doubts about the drug’s target.

Tiragolumab missed the chance to prove a survival benefit in SKYSCRAPER-01 adding to previous trial failures for the anti-TIGIT therapy.